Fibromyalgia is not currently classified as an autoimmune disease. It is categorized as a central sensitivity syndrome, a condition rooted in how the brain and spinal cord process pain signals rather than in immune system attacks on the body’s own tissues. That said, recent research has complicated this picture in surprising ways, with some studies suggesting that immune system components may play a larger role than previously thought.
How Fibromyalgia Is Currently Classified
Fibromyalgia affects over 5% of the population and is defined as a disorder of abnormal central pain processing. The core problem is neurobiological: the mechanisms that normally regulate pain sensation become dysregulated, causing the nervous system to amplify pain signals. This is sometimes called central sensitization, and it’s fundamentally different from what happens in autoimmune diseases like rheumatoid arthritis or lupus, where the immune system mistakenly attacks healthy tissue and causes measurable inflammation and tissue destruction.
The American College of Rheumatology has published diagnostic criteria for fibromyalgia (updated versions in 1990, 2010, and a modified 2010 set), but none of them rely on immune markers or antibody tests. There is no blood test that confirms fibromyalgia. In classic autoimmune diseases, doctors can typically detect specific antibodies, elevated inflammatory markers, or visible tissue damage. Fibromyalgia doesn’t produce those hallmarks in the same way.
Why Standard Inflammation Tests Come Back Different
One key distinction between fibromyalgia and autoimmune diseases shows up in basic lab work. In conditions like rheumatoid arthritis or lupus, inflammatory markers such as C-reactive protein (CRP) tend to be significantly elevated. In fibromyalgia, the picture is more subtle. Patients do show slightly higher levels of high-sensitivity CRP compared to healthy controls (an average of 2.71 versus 1.75 in one study), and those higher levels correlate with greater symptom burden and more tender points. But these elevations are modest compared to the dramatic spikes seen in active autoimmune flares.
This is one reason standard immunosuppressant treatments used for autoimmune diseases don’t work well for fibromyalgia. In rheumatoid arthritis, biologic drugs that suppress the immune system can effectively control inflammation, but even RA patients who achieve good inflammatory control often have residual pain if they also have fibromyalgia. That lingering pain appears to stem from central sensitization rather than ongoing immune activity, which is why fibromyalgia treatment typically focuses on the nervous system through pain-modulating medications, exercise, and cognitive approaches rather than immune suppression.
The Study That Challenged the Classification
A landmark 2021 study published in The Journal of Clinical Investigation introduced a significant wrinkle. Researchers purified IgG antibodies from the blood of eight fibromyalgia patients and six healthy volunteers, then injected them into mice over four consecutive days. The results were striking: antibodies from all eight patients, but none of the healthy volunteers, rapidly produced heightened sensitivity to both pressure and cold in the mice. These symptoms appeared within 24 to 48 hours and lasted more than a week.
The effects went beyond pain sensitivity. Mice that received fibromyalgia patient antibodies also showed reduced grip strength and decreased physical activity, particularly during their most active hours. Perhaps most remarkably, skin biopsies revealed that these mice lost nerve fibers in the outer layer of their skin, a finding that mirrors what’s seen in many fibromyalgia patients. When researchers used antibody-depleted serum from the same patients (meaning the blood with IgG removed), no symptoms developed. This strongly suggests the antibodies themselves were driving the problem.
Importantly, the patient antibodies did not directly activate nerve cells. Instead, they appeared to bind to structures around the nerves, altering the environment in which those nerves function. This mechanism is different from a classic autoimmune attack, where antibodies directly damage tissue, but it still places immune molecules at the center of the disease process.
Neuroinflammation in the Brain
Brain imaging studies have added another immune-related layer. Using PET scans designed to detect activated immune cells in the brain, researchers found that fibromyalgia patients show widespread elevations in brain immune cell activity compared to healthy controls. These elevations appeared across multiple brain regions involved in pain processing, sensation, and movement planning. The activated cells appear to be microglia, the brain’s resident immune cells, rather than astrocytes (another type of brain support cell).
Fibromyalgia patients also show elevated levels of specific signaling molecules in their cerebrospinal fluid that are involved in communication between neurons and immune cells. This kind of neuroimmune crosstalk could help explain central sensitization: overactive immune cells in the brain may be amplifying pain signals, blurring the line between a “purely neurological” and an “immune-mediated” condition.
Small Fiber Nerve Damage
About 49% of fibromyalgia patients show evidence of small fiber pathology, according to a meta-analysis of eight studies covering 222 participants. Small fibers are the tiny nerve endings in your skin that detect pain, temperature, and light touch. When detected through skin biopsy, the prevalence was 45%; when assessed using a specialized eye imaging technique called corneal confocal microscopy, it was 59%.
This finding matters because small fiber neuropathy is a measurable, objective abnormality, something that can be seen under a microscope. It suggests that fibromyalgia is not “all in the brain” but involves real peripheral nerve damage in a substantial number of patients. Whether this damage is caused by antibodies (as the mouse study suggests), by neuroinflammation, or by some other mechanism is still being worked out.
The Overlap With Autoimmune Conditions
Fibromyalgia frequently coexists with true autoimmune diseases, which adds to the confusion. Women with fibromyalgia are nearly six times more likely to also have lupus and about 4.5 times more likely to have rheumatoid arthritis compared to women without fibromyalgia. Men with fibromyalgia are roughly six times more likely to have rheumatoid arthritis.
This overlap raises a chicken-and-egg question. Chronic inflammation from an autoimmune disease can trigger central sensitization over time, potentially causing fibromyalgia as a secondary condition. Alternatively, whatever immune dysfunction contributes to fibromyalgia might also increase susceptibility to autoimmune disease. The relationship likely runs in both directions, and researchers now describe a “peripheral inflammation to central sensitization” axis that connects the two types of conditions.
Where the Classification Stands
The honest answer is that fibromyalgia sits in an uncomfortable gray zone. It is officially classified as a central pain processing disorder, not an autoimmune disease. Conventional autoimmune markers are absent or only mildly elevated, and immunosuppressant drugs don’t resolve its symptoms. But the antibody transfer evidence, the brain immune cell activation, and the high rate of small fiber nerve damage all point to immune involvement that doesn’t fit neatly into any existing category. Some researchers have begun describing it as an “autoimmune or immune-mediated” condition, though this remains a minority position. For now, fibromyalgia is best understood as a disorder where the nervous system and immune system interact in abnormal ways, producing real, measurable changes in how the body processes pain.